ClinicalTrials.gg
CompletedNCT02419742Updated Oct 12, 2022Results posted

Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen

A Phase 4 interventional study of Carboplatin and Cyclophosphamide in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 6 sites in India. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-12.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
110
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 145 studies testing carboplatin in Breast Neoplasms — 17 open to participants now, 34 under way, 9 of them phase 3. Carboplatin · Breast Neoplasms.

Enrollment
46th of 142
110 · median 60
Started
2015
with 10 others
Phase 4
5 of 145
3 open now
Registered
98th of 145
by date

Among the 145 studies testing carboplatin in Breast Neoplasms, this one is the 46th largest by enrollment of the 142 interventional ones that give a count, is one of 11 that started in 2015, is one of 5 in phase 4, and was the 98th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 145 studies testing carboplatin in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About carboplatin

Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 145 studies testing carboplatin in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a prospective, Phase IV, multi-center, single arm, open-label, interventional study to evaluate the safety of trastuzumab for the treatment of human epidermal growth factor receptor 2 protein (HER2)-positive node positive or high risk node negative breast cancer participants with regimen consisting of doxorubicin and cyclophosphamide followed by either paclitaxel or docetaxel (AC-TH Regimen) or a regimen consisting of docetaxel and carboplatin (TCH Regimen) in Indian population.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed early invasive positive, node positive or high risk node negative breast cancer with no evidence of residual, locally recurrent or disease and defined as clinical stage I to IIIA that is eligible for treatment with trastuzumab
  • (ECOG) performance status 0 to 2
  • HER2 over expression/amplification defined as either Immunohistochemistry (IHC)3+, or IHC2+ and Fluorescence in situ Hybridization (FISH) positive as determined in a central laboratory
  • At time of starting trastuzumab therapy, measured by echocardiography
  • Screening LVEF greater than or equal to (>/=) 55 percent (%)
  • Adequate bone marrow, renal, and hepatic function
  • Agreement to use an adequate, non-hormonal means of by women of

Exclusion criteria

Exclusion Criteria:

  • Any to trastuzumab
  • Previous breast cancer treatment with an approved or anti- agent
  • History of other , except for curatively treated carcinoma in situ of the cervix or basal cell carcinoma and participants with other curatively treated malignancies who have been disease-free for at least 5 years
  • Past history of ductal carcinoma in situ and/or lobular carcinoma that has been treated with any systemic therapy or with radiation therapy to the ipsilateral breast where the invasive cancer subsequently develops
  • Locally advanced (Stage IIIB and IIIC) and disease (Stage IV)
  • cardiovascular disorder or disease
  • Uncontrolled hypertension, or history of hypertensive crisis or hypertensive encephalopathy
  • History of severe allergic or immunological reactions, example difficult to control asthma
  • Pregnant or lactating women
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    Trastuzumab

    Participants will receive trastuzumab as a part of either AC-TH or TCH treatment regimen. The choice of the regimen will be based on investigator's discretion referring the local prescribing document of trastuzumab. AC-TH consists of doxorubicin and cyclophosphamide followed by either paclitaxel or docetaxel. TCH consists of docetaxel and carboplatin. Trastuzumab will be common in both treatment regimens and could be administered weekly or every 3 weeks, as per investigator discretion. Each cycle will be of 3 weeks.

    Drug: Carboplatin · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Doxorubicin · Drug: Paclitaxel · Drug: Trastuzumab

Interventions

  • TCH regimen: Carboplatin dose = Target Area Under Curve (AUC) (6 milligrams\*milliliter/minute \[mg\*mL/min\]) multiplied by (Glomerular Filtration Rate \[GFR\] + 25). Carboplatin will be administered as IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).

  • AC-TH regimen: Cyclophosphamide 600 mg/m\^2 IV bolus every 3 weeks for 4 cycles (Cycles 1 to 4).

  • AC-TH regimen: Docetaxel 100 mg/m\^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8). TCH regimen: Docetaxel 75 mg/m\^2 IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).

  • Participants will receive Doxorubicin 60 mg/m\^2 administered as I.V. bolus injection over 5 to 15 minute every 3 weeks for 4 cycles for AC-TH regimen.

  • AC-TH regimen: Paclitaxel 175 mg/m\^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8).

  • AC-TH regimen: For weekly administration, 4 milligrams per kilograms (mg/kg) loading dose on Day 1 of Cycle 5, followed by 2 mg/kg on Day 8 of Cycle 5 and 2 mg/kg every week for 4 cycles (up to Cycle 8). For 3 weekly administration, 8 mg/kg loading dose on Day 1 of Cycle 5, followed by 6 mg/kg every 3 for 4 cycles (up to Cycle 8). From Day 1 of Cycle 9, 6 mg/kg will be administered every 3 weeks up to Cycle 22. TCH regimen: For weekly administration, 4 mg/kg loading dose followed by 2 mg/kg weekly from Cycles 1 to Cycle 6. For 3 weekly administration, 8 mg/kg loading dose followed 6 mg/kg every 3 weeks from Cycles 1 to 6. From Cycle 7, 6 mg/kg every 3 weeks up to Cycle 18. All administrations will be intravenous (IV) infusion.

06

What researchers measure

Primary outcomes

  1. Clinically Significant Changes in Cardiac Function As Determined by Left Ventricular Ejection Fraction (LVEF) Measurements Using Echocardiography

    LVEF assessments were performed every three months (four cycles) using echocardiogram

    Time frame: Baseline to every 4 cycles up to Cycle 21 (AC-TH), every 4 cycles up to Cycle 17 (TCH) (each cycle is 21 days), at study treatment completion (12 months post baseline) at 6 month (18 months post baseline) and 12 month follow-up (24 months post baseline)

  2. Percentage of Participants With Adverse Events

    An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with the treatment. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events.

    Time frame: Baseline up to approximately 5 years and 10 months

Secondary outcomes

  1. Disease Free Survival (DFS)

    DFS was defined as time from the date of first study treatment to the date of local, regional or distant recurrence, contra-lateral breast cancer or death due to any cause. Local, regional or distant recurrence, and contra-lateral breast cancer was assessed by combination of physical examination, mammography and pelvic examination.

    Time frame: The date of first study treatment to the date of local, regional or distant recurrence, contra-lateral breast cancer or death due to any cause within 12 months from the last dose of Trastuzumab for every participant

  2. Overall Survival (OS)

    Overall survival was defined as time from the date of first study treatment until date of death, regardless of the cause of death.

    Time frame: Time from the date of first study treatment until date of death, regardless of the cause of death within 12 months from the last dose of Trastuzumab for every participant. The follow up period was 52 weeks from the last dose of treatment in both arms.

07

Results

Posted Oct 12, 2022

Participant flow

The study was conducted at 6 investigational sites in India.

Participant flow — Overall Study
MilestoneTrastuzumab With AC-TH RegimenTrastuzumab With TCH Regimen
Started5852
Completed5350
Not completed52
Withdrew: Adverse event20
Withdrew: Disease progression01
Withdrew: Withdrew consent21
Withdrew: Any other reason which the investigator deemed participant unsuitable for enrollment into the study10

Outcome measures

PrimaryClinically Significant Changes in Cardiac Function As Determined by Left Ventricular Ejection Fraction (LVEF) Measurements Using Echocardiography

LVEF assessments were performed every three months (four cycles) using echocardiogram

Time frame:
Baseline to every 4 cycles up to Cycle 21 (AC-TH), every 4 cycles up to Cycle 17 (TCH) (each cycle is 21 days), at study treatment completion (12 months post baseline) at 6 month (18 months post baseline) and 12 month follow-up (24 months post baseline)
Reported as:
Mean · Percentage of LVEF
Clinically Significant Changes in Cardiac Function As Determined by Left Ventricular Ejection Fraction (LVEF) Measurements Using Echocardiography
Percentage of LVEFTrastuzumab With AC-TH RegimenTrastuzumab With TCH Regimen
Baseline60.1 ± 6.1762.1 ± 2.30
Cycle 5-0.2 ± 4.71-0.4 ± 2.72
Cycle 9-0.5 ± 4.64-1.0 ± 2.98
Cycle 13-2.0 ± 6.94-1.0 ± 2.36
Cycle 17-1.8 ± 4.77-1.1 ± 3.15
Cycle 21-1.8 ± 4.88—
Study Completion Visit-3.3 ± 6.59-0.7 ± 2.72
6 Month Follow Up-1.6 ± 5.89-0.3 ± 3.18
12 Month Follow Up-2.2 ± 6.28-0.4 ± 2.92
PrimaryPercentage of Participants With Adverse Events

An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with the treatment. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events.

Time frame:
Baseline up to approximately 5 years and 10 months
Reported as:
Count of participants · Participants
Percentage of Participants With Adverse Events
ParticipantsTrastuzumab With AC-TH RegimenTrastuzumab With TCH Regimen
Percentage of Participants With Adverse Events4651
SecondaryDisease Free Survival (DFS)

DFS was defined as time from the date of first study treatment to the date of local, regional or distant recurrence, contra-lateral breast cancer or death due to any cause. Local, regional or distant recurrence, and contra-lateral breast cancer was assessed by combination of physical examination, mammography and pelvic examination.

Time frame:
The date of first study treatment to the date of local, regional or distant recurrence, contra-lateral breast cancer or death due to any cause within 12 months from the last dose of Trastuzumab for every participant
Reported as:
Median · Months
Disease Free Survival (DFS)
MonthsTrastuzumab With AC-TH RegimenTrastuzumab With TCH Regimen
Disease Free Survival (DFS)NA (NA to NA)NA (NA to NA)
SecondaryOverall Survival (OS)

Overall survival was defined as time from the date of first study treatment until date of death, regardless of the cause of death.

Time frame:
Time from the date of first study treatment until date of death, regardless of the cause of death within 12 months from the last dose of Trastuzumab for every participant. The follow up period was 52 weeks from the last dose of treatment in both arms.
Reported as:
Median · Months
Overall Survival (OS)
MonthsTrastuzumab With AC-TH RegimenTrastuzumab With TCH Regimen
Overall Survival (OS)NA (NA to NA)NA (NA to NA)

Adverse events

Collected over Baseline up to approximately 5 years and 10 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab With AC-TH Regimen1/56 (1.8%)11/56 (19.6%)46/56 (82.1%)
Trastuzumab With TCH Regimen1/52 (1.9%)9/52 (17.3%)51/52 (98.1%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventTrastuzumab With AC-TH RegimenTrastuzumab With TCH Regimen
DiarrhoeaGastrointestinal disorders0/562/52
Disease progressionGeneral disorders0/562/52
Febrile neutropeniaBlood and lymphatic system disorders2/560/52
NeutropeniaBlood and lymphatic system disorders2/561/52
PyrexiaGeneral disorders2/561/52
AnaemiaBlood and lymphatic system disorders0/561/52
ThrombocytopeniaBlood and lymphatic system disorders0/561/52
VomitingGastrointestinal disorders0/561/52
FatigueGeneral disorders0/561/52
Viral infectionInfections and infestations0/561/52
Most frequent other events
Showing 10 of 38
Most frequent other events
EventTrastuzumab With AC-TH RegimenTrastuzumab With TCH Regimen
AnaemiaBlood and lymphatic system disorders12/5627/52
ThrombocytopeniaBlood and lymphatic system disorders0/5622/52
LeukopeniaBlood and lymphatic system disorders22/563/52
Urinary tract infectionInfections and infestations14/563/52
AstheniaGeneral disorders0/5612/52
PyrexiaGeneral disorders12/5611/52
Pain in extremityMusculoskeletal and connective tissue disorders3/5610/52
DiarrhoeaGastrointestinal disorders3/569/52
VomitingGastrointestinal disorders0/569/52
FatigueGeneral disorders3/568/52

Baseline characteristics

Intent-to-treat (ITT) population included all participants enrolled in the study.

Age, Continuous
Age, Continuous(Years)Trastuzumab With AC-TH RegimenTrastuzumab With TCH RegimenTotal
Mean51.95 ± 7.9651.19 ± 10.9451.59 ± 9.45
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab With AC-TH RegimenTrastuzumab With TCH RegimenTotal
Female5852110
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Trastuzumab With AC-TH RegimenTrastuzumab With TCH RegimenTotal
American Indian or Alaska Native000
Asian5852110
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

6 sites
  • Yashoda Hospital
    Hyderabad, Andhra Pradesh 500082, India
  • Rajiv Gandhi Cancer Institute & Research Center
    New Delhi, Delhi 110085, India
  • Manipal Hospital; Department of Oncology
    Bangalore, Karnataka 560017, India
  • Jehangir Clinical Development Centre Pvt. Ltd; Cancer Research Room
    Pune, Maharashtra 411001, India
  • MAX Balaji Hospital
    Delhi, 110092, India
  • Dr. GVN Cancer Institute; Medical Oncology
    Trichy, 620008, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Jun 2021, 70 months.

Results were first posted in Oct 2022, 1 year 3 months after primary completion.

Of 130 phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's 70 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2015
First posted
Apr 17, 2015
StartActual
Aug 18, 2015
Primary completionActual
Jun 24, 2021
CompletionActual
Jun 24, 2021
Results first posted
Oct 12, 2022
Last update
Oct 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02419742
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 17, 2015
Start date
Aug 18, 2015
Primary completion
Jun 24, 2021
Completion
Jun 24, 2021
Results posted
Oct 12, 2022
Last update
Oct 12, 2022

Study contacts

Anil Kukreja, MD
study director · Roche Products (India) Pvt. Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carboplatin · Cyclophosphamide · Docetaxel · Doxorubicin · Paclitaxel · Trastuzumab

Start the discussion